Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9261540 | Autoimmunity Reviews | 2005 | 6 Pages |
Abstract
Rituximab is a chimeric mouse-human monoclonal antibody, which binds to CD20, a B cell surface marker, leading to cell death by complement induced lysis and apoptosis. Since the introduction of this drug in the treatment of non-Hodgkin lymphoma, its applications have been extended to autoimmune diseases. This review summarizes the actual possible uses of this novel immune system targeted drug, and explains the mechanism of B cell depletion in autoimmune diseases.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Milena Pitashny, Yehuda Shoenfeld,